Navigation Links
Novel lung cancer vaccine shows promise in fighting early-stage lung cancer
Date:4/6/2009

MAGE-A3 trial," said Kim. "This is a potential alternative for patients that otherwise would not undergo chemotherapy treatment either because of their tumor stage or other co-morbidities such as their age or other medical problems."

A total of 182 patients with non-small-cell lung cancers were included in the early phase of the study sponsored by GlaxoSmithKline, which is developing the vaccine therapy. All the patients had cancers expressing MAGE-A3, the tumor-specific antigen. After having surgery to remove the tumors, 122 patients were randomly assigned to treatment with the MAGE-A3-targeting vaccine and 60 patients received placebo vaccines. The preliminary research shows that the treatment was well tolerated by patients and the MAGE-A3-treated patients seemed less likely to have recurrences and die from their disease than the placebo-treated patients. Further studies need to be completed to test the safety and efficacy of the vaccine.

Patients were given five injections every three weeks at the beginning of treatment and then eight injections every three months later for a total of 27 months. Earlier phases of the study indicate the immunotherapy treatment was well tolerated by patients.


'/>"/>

Contact: Deborah Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. MIT: Novel needle could cut medical complications
2. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
3. Novel electric signals in plants
4. Novel veterinary procedure detecting life-threatening injuries touted
5. Forget the freezer: Research suggests novel way to control water behavior
6. Breaking the barrier: Discovery of anti-resistance factors and novel ocean drugs
7. Mayo Clinic researchers suspect a novel gene is causing restless legs syndrome in a large family
8. Fighting obesity and illness with a novel approach to nutrition
9. Novel technology could produce biofuel for around 0.50 a liter ($2.49 a gallon)
10. Novel technology could produce biofuel for around €0.50 a liter ($2.49 a gallon)
11. Studies point to novel target for treating arrhythmias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million infants, ... researchers at the University of Massachusetts Medical School, have ... can be successfully implemented across public health newborn screening ... the Aug. 20 issue of the Journal of ... the rate of SCID in newborns is higher than ...
(Date:8/20/2014)... National Institutes of Health has awarded the Oklahoma Medical ... its research on anthrax and the bacteria,s effects on ... Coggeshall, Ph.D., and his colleagues have studied the human ... Cooperative Centers for Human Immunology. The original funding came ... on the heels of the terrorist attacks of Sept. ...
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... rearrangement hotspots has its most recent addition in a ... of California San Diego. The study, published on ... are indeed rearrangement hotspots in the human genome. ... for analyzing complex rearrangements (including transpositions) which demonstrates that ...
... TEMPE, Ariz. -- Anyone who has thrown a backyard barbecue ... than buns eight hot dogs per pack versus 10 ... weenie roasts are hot-dog limited the extra buns are ... limiting factors are a cornerstone of natural ecology, where phosphorus ...
... years, researchers have suspected there must be a natural ... body and could be harnessed to develop more effective ... Currently, drugs that lower sodium levels all have serious ... at Cornell and the Boyce Thompson Institute for Plant ...
Cached Biology News:At the root of nutrient limitation, ecosystems are not as different as they seem 2At the root of nutrient limitation, ecosystems are not as different as they seem 3Researchers' discovery may lead to hypertension treatment 2
(Date:8/20/2014)...  Decision Resources Group finds that the vascular access device market ... India and China ... to the size of the United States ... much faster growth as a result of strong economic expansion, improving ... findings from Decision Resources Group,s coverage of the BRIC vascular access ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
(Date:8/20/2014)... August 20, 2014 WriteResult®, a leading ... that it has expanded its myPROpad™ ePRO tablet with ... one of the most widely used and well-respected ... health status. The EQ-5D is used during clinical trials ... measure that can be used to demonstrate Health-Related Quality ...
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... 29 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; "the ... and Earth Technology Development Corp. Ltd.,("China RainEarth") attended the ... , A good marketing strategy ... products. In the forum, participants explored various marketing,strategies and ...
... Calif., June 29 Kornberg Associates | Architects ( ... to design a new Cognitive & Neurobiological Imaging Center. ... The firm has worked with Stanford University since ... years, one of which is the two-story, 32,000 square-foot office ...
... Hutchinson Cancer Research Center board of trustees today announced that ... in June 2010. Hartwell, a recipient of the 2001 Nobel ... of the Hutchinson Center since 1997. , , ... of the Center for 12 years. It,s time for new ...
Cached Biology Technology:RainEarth (RNER) Continues to Expand its Marketing Force in China 2RainEarth (RNER) Continues to Expand its Marketing Force in China 3Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010 2
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Oct 2 Immunogen: Full length human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Biology Products: